Overview
To evaluate the stent endothelialization (> 20 microns) of VIVO ISARTM versus XIENCE SkypointTM stents at 1-month (very early strut covered) at follow-up by Optical Coherence Tomography (OCT) implanted IN THE SAME PATIENT during routine clinical practice.
Description
To evaluate the stent endothelialization (> 20 microns) of VIVO ISARTM versus XIENCE SkypointTM stents at 1-month (very early strut covered) at follow-up by Optical Coherence Tomography (OCT) implanted IN THE SAME PATIENT during routine clinical practice.
Eligibility
Inclusion Criteria:
- Patients with age ≥ 18 years AND
- Patients who have signed informed consent AND
- Patients with coronary artery disease requiring percutaneous treatment with coronary stents due to de novo lesions in vessels with a diameter of reference from 2.25 mm to 4.0 mm AND
- Patients with at least 2 angiographic lesions in 2 different major coronary arteries. Or in the main branch and in one of its subsidiaries branches , as long as those are not "downstream" of the lesion from the main branch
Exclusion Criteria:
- Express refusal of the patient to participate in the study
- Patients with ST elevation Myocardial Infarction or Cardiogenic Shock
- Patients with high thrombotic content
- Pregnant or breastfeeding patients
- Patients with complex PCI (Percutaneous Coronary Intervention )(defined as):
- Left main PC
- Chronic total PC occlusion
- Bifurcation lesion requiring 2-stent technique .
- Severe calcified lesion (need to use prior complex techniques of calcium modification
such as intravascular lithotripsy, rotational/orbital atherectomy, laser.
- Patients with malignant neoplasms or other comorbid conditions with life expectancy <12 months
- Patients with a target lesion in a bypass graft
- Lesions due to restenosis
- Patients with PCI in the target vessel in the previous 9 months
- Patients with contraindication or difficulty to evaluate in the follow-up with OCT (renal failure, excessive tortuosity or lesions aorto-ostial)